Clinical Trial Update: Ruxolitinib as a Salvage Therapy for Hemophagocytic Lymphohistiocytosis [Phase 3]

View source ↗

Summary

Phase 3 trial update assessing ruxolitinib as salvage therapy for hemophagocytic lymphohistiocytosis.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hemophagocytic Lymphohistiocytosis

Drugs mentioned

• Ruxolitinib (ruxolitinib)

Snippet

Sponsor: Beijing Friendship Hospital | Conditions: Hemophagocytic Lymphohistiocytosis | Phase 3 | Status: UNKNOWN